AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Amgen Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$230.94|
|52 Week High||US$258.45|
|52 Week Low||US$198.64|
|1 Month Change||-4.66%|
|3 Month Change||-7.06%|
|1 Year Change||10.43%|
|3 Year Change||16.24%|
|5 Year Change||26.36%|
|Change since IPO||21,424.50%|
Recent News & Updates
HHS buying $290M worth of Amgen drug Nplate for radiation sickness in nuclear emergency
HHS is purchasing $290M worth of Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for acute radiation sickness due to a radiological or nuclear emergency. The treatment was developed by the company with assistance from the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases. Nplate is approved for immune thromocytopenia, a blood disorder characterized by low platelet counts.
Amgen, AstraZeneca's Tezspire for severe asthma gets approval in EU
The European Commission (EC) approved Amgen (NASDAQ:AMGN) and AstraZeneca's (NASDAQ:AZN) Tezspire as an add-on maintenance therapy for patients 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product. Tezspire is approved in the U.S. and other countries for treating severe asthma, AstraZeneca said in a Sept. 21 press release. In July, a panel of the European Medicines Agency (EMA) recommended the approval of Tezspire (tezepelumab). The EC decision was backed by data from the PATHFINDER clinical trial program, which included a phase 3 trial called NAVIGATOR. The British pharma giant said that Tezspire is the first and only biologic approved in the EU for patients with severe asthma with no phenotype or biomarker limitations.
Amgen Lumakras/Vectibix combo shows promise in phase 1 trial in colorectal cancer
Amgen (NASDAQ:AMGN) said Lumakras in combination with its other drug Vectibix showed encouraging efficacy and safety in certain patients with colorectal cancer in a phase 1b study called CodeBreaK 101. In total, 40 patients with heavily pre-treated (median of two prior lines of therapy) KRAS G12C-mutated chemo-refractory (resistant) metastatic colorectal cancer (mCRC) were enrolled in the dose expansion group receiving Lumakras (sotorasib) and Vectibix combo, the company said in a Sept. 12 press release. Amgen said Overall, the confirmed objective response rate (ORR) was 30% in patients with chemo-refractory mCRC. Disease control was seen in 37 patients with a median progression free survival (PFS - length of time during/after therapy that a patient lives with the disease without it getting worse) of 5.7 months. Tumor shrinkage of any magnitude was seen in 88% of the patients, the company added. Amgen noted that Treatment-related adverse events (TRAEs) reported with the combination were consistent with known safety profiles of the individual drugs. In August it was reported that Lumakras led to a higher incidence of severe liver side effects in combination with immunotherapies, as per data from a phase 1 trial.
|AMGN||US Biotechs||US Market|
Return vs Industry: AMGN exceeded the US Biotechs industry which returned -19.3% over the past year.
Return vs Market: AMGN exceeded the US Market which returned -18.8% over the past year.
|AMGN Average Weekly Movement||2.8%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: AMGN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AMGN's weekly volatility (3%) has been stable over the past year.
About the Company
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Amgen Inc. Fundamentals Summary
|AMGN fundamental statistics|
Is AMGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMGN income statement (TTM)|
|Cost of Revenue||US$6.40b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||12.29|
|Net Profit Margin||24.92%|
How did AMGN perform over the long term?See historical performance and comparison